Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer

AIM: To evaluate the efficacy and safety of modified FOLFIRINOX as a second-line treatment for gemcitabine (GEM)-refractory unresectable pancreatic cancer (PC). METHODS: This study was a prospective, multicenter, one-arm, open-label, phase II trial. Patients with unresectable PC, who showed disease...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:World J Gastrointest Oncol
Egile Nagusiak: Chung, Moon Jae, Kang, Huapyong, Kim, Ho Gak, Hyun, Jong Jin, Lee, Jun Kyu, Lee, Kwang Hyuck, Noh, Myung Hwan, Kang, Dae Hwan, Lee, Sang Hyub, Bang, Seungmin
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Baishideng Publishing Group Inc 2018
Gaiak:
Clinical Trials Study
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6304301/
https://ncbi.nlm.nih.gov/pubmed/30595804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v10.i12.505
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak